Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Leukemogenesis

Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy

Abstract

Therapy-related MDS and AML are complications of intensive chemotherapy regimens. Traditionally, patients exposed to topoisomerase II inhibitors are reported to develop secondary AML with abnormalities of chromosome 11q23. We evaluated the long-term hematologic toxicity of topoisomerase II-intensive high-dose mitoxantrone-based chemotherapy in 163 newly diagnosed acute leukemia patients treated over an 8 year period. Nine (5.5%) patients developed new cytogenetic abnormalities. Four patients developed MDS with progression to AML, three patients developed new abnormalities at the time of relapse, and three patients (including one of the former patients) had changes that were not associated with hematologic disease. The abnormalities most frequently involved chromosomes 7q, 20q, 1q, and 13q. Despite the use of topoisomerase II-intensive treatment, no patient developed an abnormality involving chromosome 11q23. Spontaneous resolution of some changes and prolonged persistence of others in the absence of hematologic disease indicates that some cytogenetic changes are not sufficient to promote leukemogenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Mayer RJ, Davis RB, Schiffer CA, Berk DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, for the Cancer and Leukemia Group B . Intensive postremission chemotherapy in adults with acute myeloid leukemia N Engl J Med 1994 331: 896–903

    Article  CAS  Google Scholar 

  2. Bishop JS, Matthews JP, Young GA, Bradstock K, Lowenthal RM . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group Leuk Lymphoma 1998 28: 315–327

    Article  CAS  Google Scholar 

  3. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K . Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial Lancet 1998 351: 700–708

    Article  CAS  Google Scholar 

  4. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G . Autologous or allogeneic bone marrow transplantation compared to intensive chemotherapy in acute myelogenous leukemia N Engl J Med 1995 332: 217–223

    Article  CAS  Google Scholar 

  5. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P . Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia Blood 1995 86: 3542–3552

    CAS  PubMed  Google Scholar 

  6. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin van der Poel S, Kaneko Y, Morgan R, Sandberg AA, Chaganti RSK, Larson RA, Le Beau MM, Diaz MO, Rowley JD . Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations N Engl J Med 1993 329: 909–914

    Article  CAS  Google Scholar 

  7. Gill Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO, Rowley JD . Rearrangements of the MLL gene in therapy-related acute myelogenous leukemia in patients previously treated with agents targeting DNA-topoisomerase II Blood 1993 82: 3705–3711

    Google Scholar 

  8. Raynaud SD, Brunet B, Chischportich M, Bayle J, Gratecos N, Pesce A, Dujardin P, Flandrin G, Ayraud N . Recurrent cytogenetic abnormalities observed in complete remission of acute myeloid leukemia do not necessarily mark preleukemic cells Leukemia 1994 8: 245–249

    CAS  PubMed  Google Scholar 

  9. Imrie KR, Dube I, Prince HM, Girouard C, Crump M, Keating A . New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis Bone Marrow Transplant 1998 21: 395–399

    Article  CAS  Google Scholar 

  10. Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, Bauters F . Therapy-related acute promyelocytic leukemia: a report on 16 cases J Clin Oncol 1992 10: 1430–1435

    Article  CAS  Google Scholar 

  11. Quesnel B, Kantarjian H, Pedersen-Bjergaard J, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P . Therapy-related acute myeloid leukemia with t(8;21), inv 16, and t(8;16). A report on 25 cases and review of the literature J Clin Oncol 1993 11: 2370–2379

    Article  CAS  Google Scholar 

  12. Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, Johansson B . Chemotherapy-related and late occurring Philadelphia chromosome in AML, ALL and CML Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997 11: 1571–1574

    CAS  PubMed  Google Scholar 

  13. Lambertenghi Deliliers G, Annaloro C, Pozzoli E, Oriani A, Volpe AD, Soligo D, Lambertenghi Deliliers D, Tagliaferri E, Bertolli V, Romitti L . Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation Leukemia Res 1999 23: 291–297

    Article  CAS  Google Scholar 

  14. Chu JY, Batanian JR, Gale GB, Dunphy CH, DeMello DE . Spontaneous resolution of myelodysplastic cytogenetic abnormality developed during the treatment of leukemia J Pediatr Hematol Oncol 1998 20: 88–90

    Article  CAS  Google Scholar 

  15. Alberts DS, Young L, Mason N, Salmon SE . In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by peritoneal administration Semin Oncol 1985 12 (Suppl. 4): 38–42

    Google Scholar 

  16. Feldman EJ, Seiter K, Traganos F, Darzynkiewicz Z, Goff H, Pozzuoli M, Baskind P, Santos S, Ahmed T . Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia Leuk Lymphoma 2000 8: 309–315

    Article  Google Scholar 

  17. Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, Razis ED . Short course high-dose mitoxantrone with high-dose cytarabine is effective therapy for adult lymphoblastic leukemia Leukemia 1991 5: 712–714

    CAS  PubMed  Google Scholar 

  18. Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW . A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia Leukemia 1998 12: 865–868

    Article  CAS  Google Scholar 

  19. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC JR, Beer M, Ahmed T . A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia Leukemia 1997 11: 485–489

    Article  CAS  Google Scholar 

  20. Seiter K, Feldman EJ, Halicka HD, Deptala A, Traganos F, Burke HB, Hoang A, Goff H, Pozzuoli M, Kancherla R, Darzynkiewicz Z, Ahmed T . Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukemia Br J Haematol 2000 108: 40–47

    Article  CAS  Google Scholar 

  21. Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D . Cytarabine with high-dose mitoxantrone induces rapid complete remission in adult acute lymphoblastic leukemia without the use of vincristine or prednisone J Clin Oncol 1996 14: 2480–2485

    Article  CAS  Google Scholar 

  22. Yunis JJ . High resolution of human chromosomes Science 1976 191: 1268–1270

    Article  CAS  Google Scholar 

  23. Seabright M . A rapid banding technique for human chromosomes Lancet 1971 2: 971–972

    Article  CAS  Google Scholar 

  24. ISCN . Mitelman F (ed). An International System for Human Cytogenetic Nomenclature S Karger: Basel 1995

    Google Scholar 

  25. Papageorgio C, Seiter K, Feldman EJ . Therapy-related myelodysplastic syndrome in adults with neurofibromatosis Leuk Lymphoma 1999 32: 605–608

    Article  CAS  Google Scholar 

  26. Le Beau MW, Espinosa III R, Davis EM, Eisenbart JD, Larson RA, Green ED . Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases Blood 1996 88: 1930–1935

    CAS  PubMed  Google Scholar 

  27. Fischer K, Frohling S, Scherer SW, McAllister Brown J, Scholl C, Stilgenbauer S, Tsui L-C, Lichter P, Dohner H . Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias Blood 1997 89: 2036–2041

    CAS  PubMed  Google Scholar 

  28. Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L . Molecular anatomy of chromosome 7q deletions in myeloid malignancies: evidence for multiple critical loci Proc Natl Acad Sci USA 1998 31: 3781–3785

    Article  Google Scholar 

  29. Mahgoub N, Taylor BR, Le Beau MM, Gratiot M, Carlson KM, Atwater SK, Jacks T, Shannon KM . Myeloid malignancies induced by alkylating agents in Nf1 mice Blood 1999 93: 3617–3623

    CAS  PubMed  Google Scholar 

  30. Kurtin PJ, Dewald GW, Shields DJ, Hanson CA . Hematologic disorders associated with deletions of chromosome 20q Am J Clin Pathol 1996 106: 680–688

    Article  CAS  Google Scholar 

  31. Campbell LJ, Garson OM . The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders Leukemia 1994 8: 67–71

    CAS  PubMed  Google Scholar 

  32. Wattel E, Lai JL, Preudhomme C, Grahek D, Morel P, Bauters F, Fenaux P . De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematologic and prognostic features? Leuk Res 1993 17: 921–926

    Article  CAS  Google Scholar 

  33. Mogul MJ, Brady K, Brothman AR, Adams R, Peterson FB . Beatty PG. Myelodysplastic syndrome presenting with clonal rearrangement isolated to chromosomal region 1q Cancer Genet Cytogenet 1997 95: 210–212

    Article  CAS  Google Scholar 

  34. Fontasch C, Haase D, Freund M, Bartels H, Tesch H . Partial trisomy 1q A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 1991 56: 243–253

    Article  Google Scholar 

  35. Verhoef G, Meeus P, Stul M, Mecucci C, Caissiman JJ, van den Berghe H, Boogaerts M . Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature Cancer Genet Cytogenet 1992 59: 161–166

    Article  CAS  Google Scholar 

  36. Chen Z, Morgan R, Notohamiprodjo M, Meloni-Ehrig A, Schuster RT, Bennett JS, Cohen JD, Stone JF, Sandberg AA . The Philadelphia chromosome as a secondary change in leukemia: three case reports and an overview of the literature Cancer Genet Cytogenet 1998 101: 148–151

    Article  CAS  Google Scholar 

  37. Katsuno M, Yamashita S, Sadamura S, Umemura T, Hirata J, Nishimura J, Nawata H . Late-appearing Philadelphia chromosome in a patient with acute non-lymphocytic leukemia derived from myelodysplastic syndrome: detection of P210- and P190-type bcr/abl fusion gene transcripts at the leukaemic stage Br J Haematol 1994 87: 51–56

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seiter, K., Feldman, E., Sreekantaiah, C. et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 15, 963–970 (2001). https://doi.org/10.1038/sj.leu.2402122

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402122

Keywords

This article is cited by

Search

Quick links